Arkolith/Insider Trading/MRNS/Form 4

Braunstein Scott

CHAIRMAN AND CEO, DirectorMARINUS PHARMACEUTICALS, INC. (MRNS) · full profile →Form 4 · filed Feb 11, 2025
Net Buying
Open-Market Buys
$7K
Open-Market Sells
$0
Net Open-Market Flow
$7K
Transactions
12
3 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 11, 2025Disposed to issuer(D)180K$0.55$99K0
Feb 7, 2025Disposed to issuer(D)125K$0.55$69K180K
Aug 14, 2024Buy(P)6K$1.10$7K305K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 11, 2025Disposed to issuer(D)193K—$00
Feb 11, 2025Disposed to issuer(D)290K—$00
Feb 11, 2025Disposed to issuer(D)450K—$00
Feb 11, 2025Disposed to issuer(D)200K—$00
Feb 11, 2025Disposed to issuer(D)16K—$00
Feb 11, 2025Disposed to issuer(D)8K—$00
Feb 11, 2025Disposed to issuer(D)168K—$00
Feb 11, 2025Disposed to issuer(D)336K—$00
Feb 11, 2025Disposed to issuer(D)360K—$00

Transaction Codes

D
Disposition to the issuer
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-25-011239) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML